There are 3397 resources available
Invited Discussant 656MO, 657MO, LBA34 and 658MO
Presenter: Pamela Munster
Session: Mini oral session - Developmental therapeutics
Resources:
Slides
Webcast
1759MO - Clinical breast examination for early diagnosis of breast cancer: An Egyptian nationwide study
Presenter: Loay Kassem
Session: Mini oral session - Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA13
Presenter: Christopher Sweeney
Session: Presidential 3
Resources:
Slides
Webcast
659MO - Preliminary results from a phase I/II study of 9MW2821, an antibody-drug conjugate targeting nectin-4, in patients with advanced solid tumors
Presenter: Jian Zhang
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
1696MO - Partial orphan cancer drugs: FDA approval, clinical benefit, trials, epidemiology, price, beneficiaries, and spending
Presenter: Daniel Michaeli
Session: Mini oral session - Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
660MO - First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase I study (SGNB7H4V-001)
Presenter: Cesar Perez
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
LBA14 - Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial
Presenter: Byoung Chul Cho
Session: Presidential 3
Resources:
Abstract
Slides
Webcast
1697MO - Spending on and beneficiaries of orphan cancer drugs for ultra-rare, rare, and common diseases
Presenter: Julia Caroline Michaeli
Session: Mini oral session - Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
Invited Discussant 659MO and 660MO
Presenter: Ulrik Lassen
Session: Mini oral session - Developmental therapeutics
Resources:
Slides
Webcast
LBA15 - Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial
Presenter: Antonio Passaro
Session: Presidential 3
Resources:
Abstract
Slides
Webcast